Kolonkrebs-Screening mittels Stuhlbluttests
CRC Screening using stool blood tests
Our report is to a large extent based on the core HTA information, but we have also used other sources
Anna-Theresa Renner, Julia Bobek, Ingrid Rosian-Schikuta, Gottfried Endel, Ingrid Wilbacher, Brigitte Masteurer.
Austria - BIQG/GÖG
www.goeg.at
Austria
GÖG; HVB
1.3.2015
colorectal cancer screening, gFOBT, FIT
The Report is a national Adaptation of the EUnetHTA Core Report for CRC Screening comparin FIt and gFOBT. We translated the main results and discussed it for Austrian Settings.
Anna-Theresa Renner, Julia Bobek, Ingrid Rosian-Schikuta, Gottfried Endel, Ingrid Wilbacher, Brigitte Masteurer. Kolonkrebs-Screening mittels Stuhlbluttests. Herausgeber und Verleger: Gesundheit Österreich GmbH, Stubenring 6, 1010 Wien, Tel. +43 1 515 61, Fax +43 1 513 84 72, Homepage: www.goeg.at. http://www.goeg.at/de/BerichtDetail/Kolonkrebs-Screening-mittels-Stuhlbluttests-2014.html
The report compares two diagnostic fecal occult blood tests for detecting CRC as a screening tool. Although the two tests are very similar the available evidence tends to prefer FIT over gFOBT for a population based screening due to higher senstivity. For the cost-effectiveness the 10years simulation of consequences shows better performance for FIT in populations based screening programs (lower costs, higher effectiveness) or at least lower costs per life year gained (3.000 Euro to17.000 Euro) or QALY (400 Euro to 8.800 Euro). Best performance for FIT is reached with an organised screening whereas gFOBT is also to be used as a point-of-care-diagnostic, reduced by the higher number of wrong negative results.

Links to local report
Materials (sources for local report)